Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Eur Radiol

Retrieve available abstracts of 37 articles:
HTML format

Single Articles

    November 2022
  1. DENIFFEL D, Perlis N, Ghai S, Girgis S, et al
    Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Eur Radiol. 2022;32:7544-7554.
    PubMed     Abstract available

  2. CORNUD F, Lefevre A, Camparo P, Barat M, et al
    Post-MRI transrectal micro-ultrasonography of transition zone PI-RADS > 2 lesions for biopsy guidance.
    Eur Radiol. 2022;32:7504-7512.
    PubMed     Abstract available

    October 2022
  3. LIAO Z, Liu G, Ming B, Ma C, et al
    Evaluating prostate cancer bone metastasis using accelerated whole-body isotropic 3D T1-weighted Dixon MRI with compressed SENSE: a feasibility study.
    Eur Radiol. 2022 Oct 21. pii: 10.1007/s00330-022-09181.
    PubMed     Abstract available

    September 2022
  4. GANDAGLIA G, Giannarini G, Stabile A, Montorsi F, et al
    Should we combine systematic with MRI-targeted biopsy? Implications for the management of patients with prostate cancer.
    Eur Radiol. 2022 Sep 15. pii: 10.1007/s00330-022-09096.

  5. PANEBIANCO V, Turkbey B
    Magnetic resonance imaging for prostate cancer recurrence: it's time for precision diagnostic with Prostate Imaging for Recurrence Reporting (PI-RR) score.
    Eur Radiol. 2022 Sep 1. pii: 10.1007/s00330-022-09095.

    August 2022
  6. ROEST C, Kwee TC, Saha A, Futterer JJ, et al
    AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study.
    Eur Radiol. 2022 Aug 12. pii: 10.1007/s00330-022-09032.
    PubMed     Abstract available

  7. RUD E, Noor D, Galtung KF, Ottosson F, et al
    Validating the screening criteria for bone metastases in treatment-naive unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
    Eur Radiol. 2022 Aug 8. pii: 10.1007/s00330-022-08945.
    PubMed     Abstract available

    July 2022
  8. DONNERS R, Fotiadis N, Figueiredo I, Blackledge M, et al
    Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
    Eur Radiol. 2022 Jul 26. pii: 10.1007/s00330-022-09011.
    PubMed     Abstract available

  9. BEHESHTI M, Taimen P, Kemppainen J, Jambor I, et al
    Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study.
    Eur Radiol. 2022 Jul 21. pii: 10.1007/s00330-022-08982.
    PubMed     Abstract available

  10. HAMZAOUI D, Montagne S, Granger B, Allera A, et al
    Prostate volume prediction on MRI: tools, accuracy and variability.
    Eur Radiol. 2022;32:4931-4941.
    PubMed     Abstract available

    June 2022
  11. SUSHENTSEV N, McLean MA, Warren AY, Brodie C, et al
    The potential of hyperpolarised (13)C-MRI to target glycolytic tumour core in prostate cancer.
    Eur Radiol. 2022 Jun 22. pii: 10.1007/s00330-022-08929.
    PubMed     Abstract available

    May 2022
  12. TO MNN, Kwak JT
    Biparametric MR signal characteristics can predict histopathological measures of prostate cancer.
    Eur Radiol. 2022 May 4. pii: 10.1007/s00330-022-08808.
    PubMed     Abstract available

    April 2022
  13. MA W, Mao J, Yang J, Wang T, et al
    Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.
    Eur Radiol. 2022 Apr 29. pii: 10.1007/s00330-022-08802.
    PubMed     Abstract available

  14. BLEKER J, Kwee TC, Rouw D, Roest C, et al
    A deep learning masked segmentation alternative to manual segmentation in biparametric MRI prostate cancer radiomics.
    Eur Radiol. 2022 Apr 14. pii: 10.1007/s00330-022-08712.
    PubMed     Abstract available

  15. PADHANI AR, Haider MA, Rouviere O
    Balancing the benefits and harms of MRI-directed biopsy pathways.
    Eur Radiol. 2022;32:2326-2329.
    PubMed     Abstract available

  16. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study.
    Eur Radiol. 2022;32:2372-2383.
    PubMed     Abstract available

    March 2022
  17. GATTI M, Faletti R, Gentile F, Soncin E, et al
    mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging.
    Eur Radiol. 2022 Mar 15. pii: 10.1007/s00330-022-08595.
    PubMed     Abstract available

  18. ZHENG H, Miao Q, Liu Y, Mirak SA, et al
    Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.
    Eur Radiol. 2022 Mar 3. pii: 10.1007/s00330-022-08625.
    PubMed     Abstract available

    February 2022
  19. PENZKOFER T, Padhani AR, Turkbey B, Ahmed HU, et al
    Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI.
    Eur Radiol. 2022 Feb 23. pii: 10.1007/s00330-022-08609.

  20. DE ROOIJ M, Barentsz JO
    PI-QUAL v.1: the first step towards good-quality prostate MRI.
    Eur Radiol. 2022;32:876-878.
    PubMed     Abstract available

  21. GIGANTI F, Dinneen E, Kasivisvanathan V, Haider A, et al
    Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial.
    Eur Radiol. 2022;32:879-889.
    PubMed     Abstract available

    January 2022
  22. BITTENCOURT LK, Guricova K, Zucker I, Durieux JC, et al
    Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naive men: a large cohort validation study.
    Eur Radiol. 2022 Jan 14. pii: 10.1007/s00330-021-08407.
    PubMed     Abstract available

    December 2021
  23. MICHALLEK F, Huisman H, Hamm B, Elezkurtaj S, et al
    Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study.
    Eur Radiol. 2021 Dec 16. pii: 10.1007/s00330-021-08394.
    PubMed     Abstract available

    November 2021
  24. HOSSEINZADEH M, Saha A, Brand P, Slootweg I, et al
    Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge.
    Eur Radiol. 2021 Nov 16. pii: 10.1007/s00330-021-08320.
    PubMed     Abstract available

  25. BOSCHHEIDGEN M, Schimmoller L, Arsov C, Ziayee F, et al
    MRI grading for the prediction of prostate cancer aggressiveness.
    Eur Radiol. 2021 Nov 8. pii: 10.1007/s00330-021-08332.
    PubMed     Abstract available

    October 2021
  26. CUOCOLO R, Stanzione A, Faletti R, Gatti M, et al
    MRI index lesion radiomics and machine learning for detection of extraprostatic extension of disease: a multicenter study.
    Eur Radiol. 2021;31:7575-7583.
    PubMed     Abstract available

    September 2021
  27. HINZPETER R, Baumann L, Guggenberger R, Huellner M, et al
    Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study.
    Eur Radiol. 2021 Sep 24. pii: 10.1007/s00330-021-08245.
    PubMed     Abstract available

  28. REISCHAUER C, Cancelli T, Malekzadeh S, Froehlich JM, et al
    How to improve image quality of DWI of the prostate-enema or catheter preparation?
    Eur Radiol. 2021;31:6708-6716.
    PubMed     Abstract available

    August 2021
  29. JENTJENS S, Mai C, Ahmadi Bidakhvidi N, De Coster L, et al
    Prospective comparison of simultaneous [(68)Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer.
    Eur Radiol. 2021 Aug 10. pii: 10.1007/s00330-021-08140.
    PubMed     Abstract available

    July 2021
  30. SUSHENTSEV N, Rundo L, Blyuss O, Nazarenko T, et al
    Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
    Eur Radiol. 2021 Jul 13. pii: 10.1007/s00330-021-08151.
    PubMed     Abstract available

  31. BURA V, Caglic I, Snoj Z, Sushentsev N, et al
    MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences.
    Eur Radiol. 2021;31:4908-4917.
    PubMed     Abstract available

    May 2021
  32. PENZKOFER T, Padhani AR, Turkbey B, Haider MA, et al
    ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging.
    Eur Radiol. 2021 May 15. pii: 10.1007/s00330-021-08021.
    PubMed     Abstract available

    April 2021
  33. WALLSTROM J, Geterud K, Kohestani K, Maier SE, et al
    Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial.
    Eur Radiol. 2021 Apr 23. pii: 10.1007/s00330-021-07907.
    PubMed     Abstract available

  34. ALBERTS I, Hunermund JN, Sachpekidis C, Mingels C, et al
    The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.
    Eur Radiol. 2021 Apr 15. pii: 10.1007/s00330-021-07870.
    PubMed     Abstract available

    January 2021
  35. STEINBERG RL, Rasmussen RG, Johnson BA, Ghandour R, et al
    Prospective performance of clear cell likelihood scores (ccLS) in renal masses evaluated with multiparametric magnetic resonance imaging.
    Eur Radiol. 2021;31:314-324.
    PubMed     Abstract available

  36. SCHELB P, Wang X, Radtke JP, Wiesenfarth M, et al
    Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment.
    Eur Radiol. 2021;31:302-313.
    PubMed     Abstract available

    November 2020
  37. DELLI PIZZI A, Mastrodicasa D, Marchioni M, Primiceri G, et al
    Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach.
    Eur Radiol. 2020 Nov 19. pii: 10.1007/s00330-020-07473.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.